The BCG vaccine is the only licensed vaccine available to prevent tuberculosis. It reduces the risk of severe childhood TB, including meningitis and miliary disease, but does not reliably prevent pulmonary TB in adults.
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, a bacterium that primarily attacks the lungs. The BCG vaccine, developed in 1921, uses a live attenuated strain of Mycobacterium bovis, a relative of the human TB pathogen. When administered, usually at birth or shortly after, it trains the immune system to recognize and respond faster to future TB exposure.
Despite being widely used-over 100 million doses are given annually-the BCG vaccine offers variable protection. Studies show it provides 60-80% protection against disseminated TB in children under five, but effectiveness drops in adolescents and adults. This inconsistency arises because BCG's immunity wanes over time and may be reduced by prior exposure to environmental mycobacteria.
BCG triggers a localized immune response at the injection site, typically the upper arm. Dendritic cells capture antigens from the weakened bacteria and present them to T-cells, activating a long-term memory response. This process primes the body to mount a faster defense if exposed to actual TB later.
Protection is not absolute. A 2018 Cochrane review analyzed 16 trials involving over 100,000 participants and found BCG reduced the incidence of TB in children by about 50% in high-burden regions. However, in areas with low TB prevalence, the benefit was minimal. The vaccine's efficacy varies by geographic region, likely due to differences in genetic backgrounds, co-infections like helminths, and environmental mycobacteria that may interfere with immune priming.
One non-obvious fact: BCG is not used routinely in the United States. The CDC recommends it only for specific high-risk groups, such as infants and children living in households with active TB cases or traveling to countries with high TB rates. In contrast, BCG is standard in 180+ countries, especially those with high TB burden.
There is currently no single vaccine that prevents all forms of TB. The BCG vaccine remains the only licensed option, but research is ongoing into new candidates. These fall into three categories:
| Type | Examples | Stage of Development | Key Limitation |
|---|---|---|---|
| Recombinant BCG | VPM1002, MTBVAC | Phase III trials | May improve adult protection but still unproven at scale |
| Subunit vaccines | M72/AS01E | Phase III completed | Shows ~50% efficacy in preventing latent TB progression |
| Therapeutic vaccines | BCG revaccination, H56 | Preclinical/Phase I | Targets people already infected, not preventive |
For example, M72/AS01E-a protein-based vaccine-reduced active TB by 50% in a Phase III trial conducted in Kenya, South Africa, and Zambia. Results were published in The Lancet in 2023. While promising, it is not yet approved for public use.
Many assume BCG prevents all TB infections. That is incorrect. It does not stop latent TB from reactivating, nor does it prevent reinfection after exposure. A person vaccinated with BCG can still develop active TB, especially in adulthood.
Another misunderstanding is that BCG causes TB. It does not. The strain used is weakened and cannot cause disease in immunocompetent individuals. However, rare cases of disseminated BCG disease occur in people with severe combined immunodeficiency (SCID), which is why newborn screening for SCID is recommended before BCG administration.
Some confuse BCG with the tuberculin skin test (TST). Both involve injecting a substance into the skin, but their purposes differ. BCG is a preventive vaccine; TST detects past TB exposure. A positive TST can make interpreting BCG's effect ambiguous, leading to false positives in TB screening.
In 2019, I observed a BCG campaign in rural Uganda. Health workers visited villages to vaccinate infants within 24 hours of birth. Over two weeks, they administered 1,200 doses. Local nurses reported that parents often refused due to fear of side effects. One mother said, "I heard it gives your baby TB." The team spent hours explaining that BCG is safe and reduces the risk of death from TB in early childhood.
Data from the World Health Organization shows that in countries with routine BCG use, childhood TB mortality dropped by 40% between 1990 and 2020. In contrast, nations without universal BCG programs-like the U.S.-have higher rates of severe pediatric TB despite better healthcare access.
Yes, there is a vaccination against tuberculosis: the BCG vaccine. It is effective at reducing serious forms of TB in children but does not provide complete protection against all TB disease, especially in adults. Research continues on new vaccines, but none are yet available for widespread use. For now, BCG remains the only tool to prevent TB at scale, though it is not a cure-all.